Investigators report finding no significant difference in positive surgical margin rates among open, laparoscopic, and robotic-assisted approaches to partial cystectomy.
Each 1-month delay in radical cystectomy following diagnosis of variant histology urothelial carcinoma of the bladder was associated with a 36% increased risk of death, a study found.
In a propensity score matched analysis, robotic-assisted and open radical cystectomy for urothelial bladder cancer did not differ significantly with respect to disease recurrence and cancer-specific mortality rates.
In a phase 2 trial, a regimen of gemcitabine plus eribulin compared favorably with other regimens for the first-line treatment of cisplatin-ineligible patients with metastatic urothelial carcinoma.
Patients who undergo surgical resection of nonmetastatic upper tract urothelial carcinoma with isolated lymph node involvement have a 5-year overall survival rate of only 24%, a study found.
Uniform use of computed tomography for hematuria workups marginally increases detection of urinary tract cancers while raising the risk for secondary cancers from imaging-associated radiation, researchers concluded.
In a phase 2 trial, erdafitinib demonstrated measurable antitumor activity in 40% of patients with FGFR3-mutant advanced urothelial cancers, investigators reported.
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
In a study, median survival time was significantly shorter among patients managed nonsurgically rather than surgically for localized upper tract urothelial carcinoma.
Adjuvant chemotherapy given to patients following underwent radical surgery for locally advanced upper tract urothelial carcinoma was associated with a significantly decreased risk of tumor recurrence.
The approval was supported by data from a phase 2 multicenter, open-label, single-arm trial (N=87) of patients with locally advanced or metastatic bladder cancer with FGFR3 or FGFR2 genetic alterations that had progressed following treatment with chemotherapy.
In a large population-based study in Sweden, statin users had significant 31% increased odds of nonmuscle-invasive bladder cancer compared with nonusers.
A high monocyte-to-lymphocyte ratio and a high platelet-to-lymphocyte ratio were predictive of poor OS in patients with advanced gallbladder cancer treated with chemotherapy.
Postoperative radiation therapy with adjuvant chemotherapy prolonged disease-free survival and overall survival in patients with locally advanced urothelial carcinoma.
